D. Boral Capital LLC Facilitates $22 Million Offering for Omeros Corporation

D. Boral Capital LLC, a New York-based global investment bank, recently acted as the exclusive placement agent for Omeros Corporation (NASDAQ: OMER) in a significant financial transaction. The deal, a registered direct offering with Polar Asset Management Partners, concluded on July 28, 2025, with Omeros selling 5,365,853 shares of common stock at $4.10 per share. This transaction raised approximately $22 million, showcasing a 14% premium over the closing price on the securities purchase agreement date of July 24, 2025.

The offering was executed under a 'shelf' Registration Statement on Form S-3 (File No. 333-268269), alongside the accompanying prospectus. This strategic move not only underscores D. Boral Capital's capability in facilitating substantial capital raises but also reflects the confidence investors have in Omeros Corporation's growth trajectory and market potential.

D. Boral Capital LLC has established itself as a premier, relationship-driven investment bank, specializing in delivering strategic advisory and tailored financial solutions to middle-market and emerging growth companies. Since its inception in 2020, the firm has successfully aggregated approximately $30 billion in capital, executing around 350 transactions across a wide array of investment banking products. Its membership in FINRA and SIPC further attests to its credibility and adherence to regulatory standards.

This transaction is a testament to D. Boral Capital's expertise in navigating the complexities of the financial markets to secure capital for its clients. For more information on D. Boral Capital's services and achievements, visit https://dboralcapital.com/.

The successful closure of this offering not only provides Omeros Corporation with the necessary capital to pursue its strategic initiatives but also reinforces the importance of having a skilled placement agent like D. Boral Capital in securing investments at a premium. This development is significant for the biotechnology sector, as it demonstrates the ongoing investor interest in funding innovative companies poised for growth.